Printer Friendly

UCI MEDICAL SCHOOL ADOPTS FIRST CERVICAL SCREENING IN 50 YEARS.

Amid ongoing questions regarding the reliability of the standard Pap smear test, the medical school of the University of California at Irvine is the first to adopt the new PapSure(TM) test into its resident teaching program.

This new Food and Drug Administration-cleared in vivo cervical screening test has been proved to have an accuracy level of 90 percent, compared with just 50 percent for the standard 50-year-old Pap smear. With the adoption of this test as part of medical residents' training, PapSure is likely to become a part of routine gynecological exams in the near future.

Made available through the Southern California-based Trylon Corp., PapSure has been clinically tested on more than 10,000 women and is the only in vivo cervical screening test available to date.

According to Dr. Vivian Dickerson, director of General Obstetrics and Gynecology at UC Irvine: "Cervical cancer is nearly 100 percent treatable when caught early. It is therefore vital for our residents to learn new techniques that improve our ability to detect disease in the earliest stages. We incorporated PapSure into our program back in March of this year."

The PapSure exam is a procedure in which a physician can directly inspect cervical tissues for abnormalities, in contrast to the Pap smear, which involves evaluating cells collected from the surface of the cervix using a laboratory microscope.

Dr. Anita Nelson, professor, Department of Obstetrics and Gynecology at Harbor-UCLA Medical Center, who is evaluating PapSure at the university in consideration of adopting the procedure into its resident program, reported: "This fall, we initiated a study with PapSure to find out how best to use it in evaluating women whose Pap smears may indicate a problem. We see this as an important dimension to cancer screening -- one which has never been available before."

PapSure puts the diagnosis back into the doctor's hands, rather than relying exclusively on laboratory screening.

According to the American College of Obstetrics and Gynecology (ACOG), while the Pap smear has done much to promote cervical health, it has limitations. According to ACOG, the Pap smear alone misses nearly as much disease as it finds, giving it just a 51 percent accuracy level.

In the face of the staggering report that nearly half of the 15,000 women who develop cervical cancer each year have had a recent Pap smear, news of this new in vivo test has brought resounding approval from local physicians and gynecologists who have already incorporated this new procedure into their practice.

About The Trylon Corp.

The Trylon Corp. is a medical-device company in the forefront of advanced light technology. The corporation is committed to using dedication, innovation and education to create effective medical products that advance the quality of life worldwide.

A pioneer in bringing chemiluminescent devices to the field of medical endoscopy, using chemical light for anatomic illumination, The Trylon Corp. has most recently completed years of research and clinical trials in developing its PapSure(TM) examination, an adjunct to the Pap smear for cervical screening.

The Trylon Corp. has headquarters in Torrance, Calif.

For more information, call 310/556-4443.
COPYRIGHT 2000 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:UCI MEDICAL SCHOOL ADOPTS FIRST CERVICAL SCREENING IN 50 YEARS.
Publication:Biotech Equipment Update
Geographic Code:1USA
Date:Feb 1, 2000
Words:514
Previous Article:ARTHROCARE GETS FDA MARKET CLEARANCE FOR SPINAL SURGERY SYSTEM.
Next Article:CARDIODYNAMICS SELLS 2ND CARDIAC MONITORING SYSTEM TO NASA.
Topics:


Related Articles
The ultimate goal? It depends.
New developments in cervical cancer detection.
The Pap smear: a victim of its own success?
Digene's chairman/CEO Evan Jones: discusses disease-specific molecular diagnostic tests, women's health issues and consumer health advocacy. (Expert...
Pap plus HPV screens save lives.
Health messages reach women through netball.
Seminar spotlights tests for cancer-causing virus.
UCI meets with UNOS in effort to get liver transplant program reinstated.
Gen-Probe Begins United States Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters